AU2002364277A1 - Method for the assessment and prognosis of sarcoidosis - Google Patents

Method for the assessment and prognosis of sarcoidosis

Info

Publication number
AU2002364277A1
AU2002364277A1 AU2002364277A AU2002364277A AU2002364277A1 AU 2002364277 A1 AU2002364277 A1 AU 2002364277A1 AU 2002364277 A AU2002364277 A AU 2002364277A AU 2002364277 A AU2002364277 A AU 2002364277A AU 2002364277 A1 AU2002364277 A1 AU 2002364277A1
Authority
AU
Australia
Prior art keywords
sarcoidosis
prognosis
assessment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002364277A
Other languages
English (en)
Other versions
AU2002364277A8 (en
Inventor
Salah-Dine Chibout
Olivier Grenet
Jeanne Kehren
Frank Stadtler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002364277A1 publication Critical patent/AU2002364277A1/en
Publication of AU2002364277A8 publication Critical patent/AU2002364277A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002364277A 2001-11-29 2002-11-28 Method for the assessment and prognosis of sarcoidosis Abandoned AU2002364277A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33426401P 2001-11-29 2001-11-29
US60/334,264 2001-11-29
PCT/EP2002/013448 WO2003046578A2 (en) 2001-11-29 2002-11-28 Method for the assessment and prognosis of sarcoidosis

Publications (2)

Publication Number Publication Date
AU2002364277A1 true AU2002364277A1 (en) 2003-06-10
AU2002364277A8 AU2002364277A8 (en) 2003-06-10

Family

ID=23306395

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002364277A Abandoned AU2002364277A1 (en) 2001-11-29 2002-11-28 Method for the assessment and prognosis of sarcoidosis

Country Status (5)

Country Link
US (1) US20050032062A1 (https=)
EP (1) EP1454145A2 (https=)
JP (1) JP2005510251A (https=)
AU (1) AU2002364277A1 (https=)
WO (1) WO2003046578A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512835A (ja) * 2003-12-05 2007-05-24 アンジオジェネティクス・スウェーデン・エイ・ビー 新脈管形成に影響を与えるポリペプチド、タンパク質及び組成物、及びそれを使用する方法
WO2006017156A2 (en) * 2004-07-09 2006-02-16 Regeneron Pharmaceuticals, Inc. Methods for identifying a candidate for treatment of obesity
JP4512828B2 (ja) * 2005-04-12 2010-07-28 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
WO2010151599A1 (en) * 2009-06-23 2010-12-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Human leukocyte antigen alleles associated with advanced lung diseases
US20110111437A1 (en) * 2009-10-08 2011-05-12 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers For Prognosis of Pulmonary Diseases
JP5120570B2 (ja) * 2010-02-15 2013-01-16 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP5574348B2 (ja) * 2012-05-31 2014-08-20 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2016141347A2 (en) * 2015-03-04 2016-09-09 Wayne State University Systems and methods to diagnose sarcoidosis and identify markers of the condition
WO2022174067A1 (en) * 2021-02-11 2022-08-18 The Board Of Trustees Of The Leland Stanford Junior University Methods relating to anti-il-1 therapy and anti-il-6 therapy and hypersensitivity
WO2025230589A1 (en) * 2024-04-29 2025-11-06 Wayne State University Peptide-based sarcoidosis immunodiagnostics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014067A1 (en) * 1992-12-14 1994-06-23 T Cell Sciences, Inc. Diagnosis and therapy of sarcoidosis

Also Published As

Publication number Publication date
EP1454145A2 (en) 2004-09-08
WO2003046578A2 (en) 2003-06-05
WO2003046578A3 (en) 2004-03-25
US20050032062A1 (en) 2005-02-10
JP2005510251A (ja) 2005-04-21
AU2002364277A8 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
AU2002364277A1 (en) Method for the assessment and prognosis of sarcoidosis
AU2002364528A1 (en) Bio-implant and method of making the same
AU2003207443A1 (en) Method and system for providing third party authentification of authorization
EP1574080A3 (en) Method and system for providing third party authentification of authorization
AU2002320456A1 (en) Removable stent and method of using the same
AU2003282558A1 (en) Nanopellets and method of making nanopellets
AU2002246957A1 (en) Smart-caching system and method
AU2003254803A1 (en) Sliding part and method of manufacturing the sliding part
IL163845A0 (en) Method and system for the automaticplanning of experiments
AUPS166202A0 (en) Authentication system and method
GB2386906B (en) Heat-resisting steel and method of manufacturing the same
AU2002349661A1 (en) Sintered object of silicon monoxide and method for producing the same
AU2003225471A1 (en) System and method of authentifying
AU2003276398A1 (en) Shearwall structure and method of making the same
AU2003259691A1 (en) An enhanced diamond and method for making the same
AU2002309200A1 (en) Microelctronic device and method of its manufacture
AU2003209534A1 (en) The method of treating tuberculosis
AU2003298332A1 (en) Secure smartcard system and method of operation
AU2003255785A1 (en) Method of authentication
AU2003212234A1 (en) Method and arrangement for the contactless determination of the direction of viewing
AU2002256277A1 (en) Soifet and method therefore
HU0102640D0 (en) Method and apparatus for the determination of the type of parachromatism
AU2002234625A1 (en) Method and arrangement for the provision of data
AU2002330993A1 (en) Improved biosensor and method
AU2002337042A1 (en) Method and means for the determination of total acid

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase